Lucia D. M.
- Country
- Italy
- Department
- Clinica di Oncologia Medica
Research Overview
- Dexamethasone Premedication to Prevent Grade ≥2 Interstitial Lung Disease in Breast Cancer Patients Receiving Trastuzumab Deruxtecan
- Evaluation of Trastuzumab Deruxtecan in Unresectable/Metastatic HER2-low or HER2 IHC0 Breast Cancer: A Multicenter, Open-label Study
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Data & Insights
Has run more than one trial at 418 of 763 partner sites.
Specializations
Advanced Breast Cancer Treatment
Specializes in investigating novel therapeutic approaches for hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on treatments following progression on standard therapies.
- Endocrine therapy combinations
- CDK4/6 inhibitor-based treatments
- ESR1 mutation-targeted therapies
Focuses on developing treatment strategies for patients who have progressed after initial therapies.
HER2-Positive Disease Management
Conducts research in HER2-positive breast cancer treatment modalities, exploring both early-stage and metastatic settings.
- Antibody-drug conjugates
- Targeted combination therapies
- Neoadjuvant treatment approaches
Investigates innovative therapeutic strategies for high-risk HER2-positive disease.
Triple-Negative Breast Cancer
Investigates treatment options for triple-negative breast cancer (TNBC), focusing on both early-stage and metastatic disease settings.
- Immunotherapy approaches
- Novel targeted therapies
- Treatment sequencing strategies
Explores innovative therapeutic options for patients with limited treatment alternatives.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.